absence epilepsy see childhood absence epilepsy; juvenile absence epilepsy
absence status 128–9
absences (absence seizures) 32–3, 39–40
  atypical, Dravet syndrome 12
differential diagnosis 40
accidental deaths 47, 109–10
accidents 47–8, 109–10
acetazolamide 96
ACTH therapy 17–18, 62–3
acute presentation of seizures 30–1
acute symptomatic seizures 1, 5, 30
adherence see compliance
adolescent-onset epilepsies 73–105
cognitive and social outcomes 99–100
common epilepsy syndromes 79–88
diagnostic problems 74–9
drug treatment 88–92
restrictions 92
treatment 95–9
triggers 92–5
adolescents
effects of puberty on established epilepsy 74
incidence of epilepsy 73–4, 74
management of cognitive and behavior problems 101
transition to adult epilepsy services 102–4
adrenoleucodystrophy 88
adverse effects of antiepileptic drugs see side effects of antiepileptic drugs
adverse seizures 37
alcohol use 93–4
Alpers’ disease 16, 22, 116
anger, paroxysmal 36–7
anoxic epileptic seizure 34
anoxic seizures, reflex 2, 34, 76
antidepressants, interactions with 118
antiepileptic drugs (AEDs)
adolescent-onset epilepsies 88–92
appropriate use 138, 141
childhood-onset epilepsies 53–4, 54–5, 55
combination therapy 22–3, 46, 89, 97, 138
compliance or adherence 20, 45–6, 91–2
duration of treatment 56–7, 90
failure of first choice 22–3, 53
further trials 58
generic and proprietary forms 89–90
infant-friendly formulations 16
infantile epilepsies 15–16
missed doses 46
refractory epilepsy see intractable epilepsy
relapse risk after withdrawal 57, 90, 112–13
risks and hazards 115–19
serum concentration monitoring 16, 46
withdrawal 57, 90–1, 112–13
anxiety 49, 51, 120
astatic seizures 42
Atkins diet, modified 24
atonic seizures 42, 43
attention deficit hyperactivity disorder (ADHD) 49, 50, 120
atypical benign partial epilepsy of childhood 58
aura 83–4, 85
autism 51–2
autonomic symptoms 84, 85
autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) 36
Index

diagnosis of epilepsy (cont.)
incorrect 139
prevention of wrong 134
reviewing 52
diazepam, rectal 115, 126
Doose syndrome see myoclonic-astatic epilepsy
Down syndrome (trisomy 21) 8, 21
Dravet syndrome (severe myoclonic
epilepsy of infancy) 12–13
ketogetic diet 25, 61
prognosis 26, 111
treatment 19, 20, 22, 58
drop attacks, epileptic 33, 42, 43, 109
drowning 47, 109
dual pathology 59
dysembryoblastic neuroepithelial tumor (DNET) 59
EEG see electroencephalography
electrical status epilepticus of slow-wave sleep
(ESESS) 38, 130
management 52, 62–3
prognosis 66
electrocardiogram (ECG) 77
electroencephalography (EEG)
invasive monitoring 59
misinterpretation 52, 140
role 2–3
encephalitis 135
epilepsia partialis continua (EPC) 131
epilepsy, defined 1
epilepsy surgery 23–4, 97–9, 61
epilepsia partialis continua 131
palliative 23, 60–1
resective 23, 60
withdrawal of medication after 57
epilepsy syndromes 3
common, in early infancy 9–14
presenting in adolescence 79–88
presenting in childhood 39–44
usefulness of concept 39
epilepsy with grand mal on awakening 79
epileptic encephalopathy 6, 42–4, 62–3
epileptic spasms 45
episodic dyscontrol disorder 36–7
ethosuximide 54
eyelid myoclonia with absences 40
falls 33
non-epileptic 33
with abnormal movements or convulsions 33–4
family
adjustment 21, 121
information provision 141
non-epileptic attack disorder 77–8
transition to adult epilepsy services and
103–4
family history 6
fear, paroxysmal 37
febrile seizures 5, 30–1
Dravet syndrome 12
investigations 30–1
prevention 136–7
felbamate 54, 117
first aid, seizure 114
first unprovoked seizures 2, 110–11
focal (partial) epilepsies
adolescent-onset seizures 82–6, 95–6
childhood-onset 58
social and cognitive outcomes 100–1
see also idiopathic partial epilepsies;
symptomatic partial epilepsies
focal (partial) seizures
absences 40
in adolescents 83
in childhood 33, 37
in infants 5
with normal imaging 44
folic acid supplements 54, 94, 118
phenytoin 127
fractures 47–8
frontal lobe epilepsy/seizures 36, 85–6
functional neuro-imaging 85
GABA-B gene mutations 13
gabapentin
focal epilepsies 55, 95–6
side effects 118
worsening of epilepsy 53
GABRG2 gene mutations 42
generalized epilepsy with febrile seizures plus
(GEFS+) 40, 42, 136
generalized tonic-clonic seizures (GTCS)
in childhood absence epilepsy 40
in infants 5
in juvenile myoclonic epilepsy 79, 80
versus syncope 34–5
genetic disorders 6
gingival hyperplasia 117
glucose transporter-1 (GLUT-1) deficiency 9, 14,
24, 61
hallucinations 37
hazards of epilepsy see risks and hazards of
epilepsy
head injuries 47–8, 109, 135–6
helmets 47, 109
hematological disorders, drug-induced 116
hemiconvulsion, hemiplegia and epilepsy (HHE) 113
history, clinical 2, 3, 29–30, 74–5
hormonal treatment, West syndrome 17–18, 23
hypoxic–ischemic encephalopathy, neonatal 20, 135
hypsarrhythmia 11, 129
  treatment 16, 17
idiopathic childhood occipital epilepsy of Gastaut 41–2
idiopathic generalized epilepsies (IGE)
  adolescent-onset 79–82
  childhood-onset 53–4, 65
  otherwise unclassifiable 79
idiopathic partial epilepsies, childhood-onset 53, 55, 64, 66
immunizations 20–1
inborn errors of metabolism 8–9, 22
incontinence 2
independence, limitations to 48
infantile epilepsies 5–27
  benign 14–15, 20, 26–7
  co-morbidities 21
  common syndromes 9–14
  early treatment 15–20
  epilepsy surgery 23–4
  family adjustment 21
  incidence 5
  ketogenic diet 24–5
  middle treatment 20–5
  prognosis 25–7
  symptomatic 6–9
  infantile seizures, benign 14–15, 26–7
  infantile spasms 5, 10, 11–12
  see also West syndrome
infections, central nervous system 135
information provision, to families 141
injuries, physical 47–8, 109–10
intellectual disability see learning difficulties
intensive care (therapy) unit 128, 131
intermittent explosive disorder 36–7
intracranial pressure, acutely raised 30
intractable (medically refractory) epilepsy 23, 57–8
  incorrect labeling 140
  perceived impact of 121–2
  predictors 64
  risk of 113
  see also epilepsy surgery
intravenous immunoglobulin (IVIG) 63, 131
juvenile absence epilepsy (JAE) 40, 79
  effect of puberty on incidence 73–4
  prognosis 65
juvenile myoclonic epilepsy (JME) 79–82
  effect of puberty on incidence 73–4
  management 81–2
  outcomes 99–100, 111–12
photosensitivity 87, 92
  risk of relapse 81–2, 112
seizure types 40, 79
  versus progressive myoclonic epilepsy 86–7
ketogenic diet 24–5, 55, 61–2
  in adolescence 96
  in non-convulsive status epilepticus 131
lacasamide 55
Lafora body disease 87
lamotrigine
  adolescent-onset epilepsies 81, 89, 95–6
  childhood-onset epilepsies 53, 54, 55
side effects 116
Landau–Kleffner syndrome (LKS) 38, 58, 63, 129, 130
learning difficulties 21, 49–50, 65, 100
  management in adolescents 101
transition to adult epilepsy services 103–4
  see also developmental regression
Lennox–Gastaut syndrome (LGS) 43–4
  management 34, 61, 63
  prognosis 65, 66, 111
levetiracetam
  childhood-onset epilepsies 54, 55
  infantile epilepsies 16
  side effects 118
  status epilepticus 127
liver toxicity 116–17
lumbar puncture 30–1
magnetic resonance imaging (MRI) 3–4
  adolescent-onset epilepsies 84–5
  childhood-onset epilepsies 31, 44
misinterpretation 140
  pre-surgical 59
magnetic resonance spectroscopy (MRS) 85
male reproductive function 95
mannerisms 35
marijuana use 93–4
Matthews Friends 62
medically refractory epilepsy see intractable epilepsy
medication dispensers 46
medico-legal aspects 139–42
medium chain triglycerides (MCT) 24
meningitis 135
menstruation 94
mental handicap/retardation see learning difficulties
metabolic disorders 8–9, 22
methylphenidate 50
methylprednisolone 62–3
midazolam
buccal 115, 126
intravenous infusion 128
migrating partial seizures in infancy (MPSI) 13–14, 25, 26
missed doses 46
mitochondrial diseases 88
molecular testing 13
Morrell’s procedure (multiple subpial transection) 61, 130
mortality risks 110, 113
motor behaviors, bizarre 37
movement abnormalities, paroxysmal 35
multiple ligation-dependent probe amplification (MLPA) 8
multiple subpial transection (MST) 61, 130
myoclonic–astatic epilepsy (MAE) (Doose syndrome) 40, 42–3
management 61
prognosis 65, 66
myoclonic epilepsies
benign, of infancy 15, 27, 111
juvenile see juvenile myoclonic epilepsy
progressive (PME) 58, 86–8, 96–7
severe, of infancy see Dravet syndrome
myoclonic seizures 5, 12
myoclonus 80, 87
narcolepsy 37
National Institute for Health and Clinical Excellence (NICE) 88, 90, 142
neonatal hypoxic–ischemic encephalopathy 20, 135
neonatal–infantile seizures, benign familial 15
neuro-degenerative disorders 22, 43
neuro-glycopenia 9
neuro-imaging 3–4
acute seizures 31
adolescent-onset epilepsies 83
functional 85
neuronal ceroid lipofuscinosis, juvenile 88
night terrors 35–6, 85
nitrazepam, West syndrome 19
non-epileptic attack disorder (NEAD) 35, 77–5
non-epileptic paroxysmal disorders 75–9
nurseries 20
obesity 119
oral contraceptive pill 94, 96, 117
oxcarbazepine 55, 95–6
Panayiotopoulos syndrome (early-onset benign occipital epilepsy) 41
management 55
prognosis 63–4, 111
parasomnias 35–6
paroxysmal disorders, non-epileptic 75–9
partial epilepsies see focal epilepsies
partial seizures see focal seizures
perioral myoclonia with absences 40
phenobarbital
in Dravet syndrome 19
side effects 116, 117–18
phenytoin 22, 89, 97
side effects 116, 117–18
status epilepticus 127
photoparoxysmal response (PPR), Dravet syndrome 13
photosensitivity 87, 92
piracetam 96–7
polypharmacy 22–3, 46, 89, 97, 138
posiion emission tomography (PET) 85
post-traumatic epilepsy (PTE) 135–6
prednisone/prednisolone 17–18, 62–3
pregnancy 54, 81, 94, 117–18
prevention 133–8
primary and secondary familial epilepsies 134
wrong diagnosis 134
wrong treatment 137–8
progressive myoclonic epilepsies (PME) 58, 86–8, 96–7
propofol 128, 131
provocative stimuli, avoidance of 92–3
provoked seizures see symptomatic seizures
pseudo-epileptic seizures see non-epileptic attack disorder
psychogenic non-epileptic seizures (PNES) see non-epileptic attack disorder
psychological problems 120–1
psychosis 49, 51, 118
psychosocial risks and hazards of epilepsy 119–22
puberty
effects on established epilepsy 74
incidence of epilepsy during 73–4, 74
purple hand/glove syndrome 127
pyridoxine dependency 9, 19
pyruvate dehydrogenase complex deficiency 24, 61
quality of life 119–21
rage, paroxysmal 36–7
rashes, drug-induced 116
Rasmussen's syndrome 63, 98, 111, 131
recreational drug use 93–4
recurrence risks
  after AED withdrawal 57, 90, 112–13
  seizures 2, 110–11
reflex anoxic seizures 2, 34, 76
refractory epilepsy see intractable epilepsy
regression see developmental regression
remission, likelihood of 111–12
restrictions, safety 47–8, 92, 109–10
ring chromosome 20 8
risks and hazards of epilepsy 108–23
  antiepileptic medication 115–19
  minimizing 114–15
  perception and prevention 123
  psychosocial 119–22
  seizure-related 109–14
road traffic accidents, prevention 136
Royal College of Paediatrics and Child Health (RCPCH) 89
rufinamide 54
school 78, 121
SCN1A gene mutations 12, 13, 42
SCN1A-related epileptic encephalopathies 12–13
SCN1B gene mutations 42
SCN2A gene mutations 15
SCN2B gene mutations 13
Scottish Intercollegiate Guidelines Network (SIGN) 88, 142
seizures
  acute presentation 30–1
  clinical diagnosis 2
  first aid for 114
  first unprovoked 2, 110–11
  inaccurate classification 140
  minor 2
  presentation and differential diagnosis 32
  prolonged, treatment 114–15
  risks and hazards related to 109–14
  symptomatic see symptomatic seizures
  triggers 92–5
  self-empowerment 102
  self-esteem, poor 120
  severe myoclonic epilepsy of infancy (SMEI) see Dravet syndrome
sexual abuse 78
sexuality 94–5
side effects of antiepileptic drugs 115–19, 138
  assessment 46
  cognitive and behavioral 51, 118–19
dose-related 115–16
  idiosyncratic reactions 116–17
  in infancy 16, 22
  long-term 117
  teratogenicity 117–18
  weight gain and obesity 119
  single photon emission computed tomography (SPECT) 85
sleep
  deprivation 93
  disruption 49, 51
  events during 35–6
social growth, limitations to 48
social isolation 101, 122
social outcome, long-term 99–100, 122, 66
sodium valproate see valproic acid/sodium valproate
sports participation 48
staring episodes 32–3
status epilepticus 126–31
  convulsive (CSE) 126–8
  inappropriately managed 141
  management 126–8, 137
  refractory (RCSE) 128
  risks 113–14
  non-convulsive (NCSE) 37, 128–31
  failure to diagnose 140
  treatment to minimize risks 114–15
stereotypies 35
steroid therapy see corticosteroid therapy
Stevens–Johnson syndrome 116
subacute sclerosing panencephalitis (SSPE) 88
submersion injuries 47, 109
sudden unexpected (or unexplained) death in epilepsy (SUDEP) 110, 141
suicide risk 118
sulthiame 55
surgery, epilepsy see epilepsy surgery
swimming 47, 109
symptomatic epilepsies 6–9, 44
  childhood-onset 53, 54–5, 62–3
  prognosis 65, 66
symptomatic focal (partial) epilepsies
  childhood-onset 53, 55, 61
  prognosis 65, 66
symptomatic seizures
  acute 1, 5, 30